Provectus Updates Shareholders on 2009 Year-to-date Accomplishments
Progress Made In Therapies for Metastatic Melanoma, Atopic Dermatitis and Psoriasis
Highlights and video from the poster presentation made at ASCO 2009
6th International Symposium on Melanoma and Other Cutaneous Malignancies
Professor John F. Thompson,M.D. presentated interim results of the phase 2 clinical trial of PV-10 for melanoma in March 2009.
Perspectives In Melanoma Conference XII Presentation
Professor John F. Thompson,M.D. presented interim results of Phase 2 PV-10 for melanoma trial in October 2008.
PV-10 for Melanoma Story Airs in Australia
Video interviews with Professor John Thompson and a patient who was involved in the Phase 2 study of PV-10 for melanoma.
Professor John Thompson of the Sydney Melanoma Unit presents preliminary findings from Phase 2 study of PV-10 for melanoma.
30 second preview of Provectus' multimedia annual report.
Clinical trial information at ClinicalTrials.gov
Summary of the clinical effects of PV-10 on melanoma
Melanoma Research Publishes PV-10 Article
[video] PV-10 for melanoma story airs on Australian TV
Information on the Compassionate Use Program for PV-10
Opening
a New Front in the
War Against Cancer
Provectus Pharmaceuticals is developing advanced therapies designed to:
Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.
For further information, read our detailed Research Reports.
Legal Notice ©2002-2009 Provectus Pharmaceuticals
CFO Peter Culpepper answers questions regarding Provectus ongoing clinical programs, developmental plans including possible partnerships, and future corporate direction in an interview appearing November 2, 2009 in The Wall Street Transcript.
The article is available for viewing here.
July 9, 2009The Morning Call recently published an article entitled "Once a wool dye, chemical could one day be a skin cancer treatment" that includes comments by Dr. Sanjiv Agarwala and a melanoma patient who participated in the Phase 2 clinical trial of PV-10 currently being conducted at St. Luke's Cancer Center.
June 2, 2009St Luke's Hospital of Bethlehem, PA issued a news release entitled Provectus Reports Encouraging Clinical Data at ASCO on Treatment of Metastatic Melanoma with PV-10. The article includes a detailed background and summary of the data presented at ASCO 2009.
June 2, 2009A Knoxville News Sentinel article appearing June 2, 2009 reports on Provectus' encouraging interim results of the PV-10 for melanoma Phase 2 clinical trial.
October 23, 2008In a Next Generation Pharmaceuticals article entitled "The Virtual Company", Provectus CFO Peter Culpepper discusses Provectus' business model with interviewer Willem van Leeuwen, Managing Director of QMR Technology B.V.
August 19, 2008The 7:30 Report, a highly acclaimed ABC current affairs program airing in Australia, recently ran a story on the treatment of melanoma with PV-10.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data. Survival data for the Phase 1 study of PV-10 for metastatic melanoma continues to show markedly longer overall and disease specific survival for subjects that were responsive to PV-10 relative to those who did not experience a robust response. Survival data was available through early November 2009.
Read the complete article here.
November 17, 2009KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.
Read the complete article here.
October 14, 2009KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States.
Read the complete article here.
October 13, 2009KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.
Read the complete article here.
October 1, 2009KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company's lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.
Read the complete article here.
September 21, 2009KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma.
Read the complete article here.
ASCO 2009 Presentation
SCC 2008 Presentation
Provectus Preview